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BACKGROUND: Various molecular mechanisms are operative
in altering the sarcomeric function of the heart under increased
hemodynamic workload. Expression of the atrial isoform (ALC-1)
of the essential myosin light chain, a shift from α-myosin heavy
chain (MHC) to β-MHC, increased phosphorylation of the regula-
tory myosin light chains and increased troponin I (TnI) phospho-
rylation have been reported to modulate cardiac contractility in
rodents.
METHODS: To assess a possible contribution of these sarcomeric
proteins to cardiac performance in human myocardial hypertrophy,
two different forms of cardiac hypertrophy were investigated: 19
patients with hypertropic obstructive cardiomyopathy (HOCM)
and 13 patients with aortic stenosis (AS) with marked left ventric-
ular hypertrophy and normal systolic function.
RESULTS: There was no change in MHC gene expression,
regulatory myosin light chain or TnI phosphorylation status in
normal heart (NH), HOCM and AS patients. However, patients
with hypertrophied myocardium expressed ALC-1 that was not
detectable in NH. ALC-1 protein expression correlated positively
with the left ventricular ejection fraction. In patients with
hypertrophied myocardium, there was a mean ALC-1 protein
expression of 12.7±3% (range 3.6% to 32%).
CONCLUSION: In humans, ALC-1 expression is in vivo a
powerful molecular mechanism of the sarcomere to maintain or
improve myocardial contractility under increased hemodynamic
demands.
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Cardiac hypertrophy is an adaptive response thatnormalizes wall stress and compensates for increased
workload. It is accompanied by qualitative and quantitative
changes in the expression of sarcomeric proteins. These
alterations have an impact on contractility, intracellular
Ca2+ homeostasis and metabolism. Changes in the myosin
subunit composition improve contractility by an increase in
force generation at a given Ca2+ concentration (1).
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Phosphorylation of the regulatory myosin light chain
(MLC) can also improve cardiac performance (2).
Additionally, phosphorylation of troponin I (TnI) leads to a
decreased affinity of contractile proteins to Ca2+ (3). In this
study, the focus is on the functional significance of myosin
heavy chain (MHC) and MLC expression, and the phos-
phorylation of TnI and the regulatory MLC in the hyper-
trophied human ventricle. The myosin muscle motor
consists of two heavy chains (MHC) and two pairs of light
chains (MLC). The MHCs can be divided into the α- and
the β-MHC isoforms (4). During development and under
pathophysiological conditions, the expression of the two
cardiac isoforms is regulated in a tissue-specific manner. In
all mammalian species, α-MHC is expressed in the atria
thoughout life. In rodents, α-MHC is also the predominant
isoform in the ventricle of adult hearts. β-MHC is expressed
in the embryonic ventricular tissue. In rodents, there is a
switch from α-MHC to β-MHC under hemodynamic stress
(5). β-MHC has reduced ATPase activity and increased
economy of isometric force development (6). In humans,
β-MHC is the predominant isoform in the adult heart (7).
Whether there is a switch under increased workload in the
human ventricle is still a matter of debate and is investigated
in this study.
MLCs are classified into essential MLC (MLC-1)
and regulatory (phosphorytable) MLC (MLC-2) (8,9).
(Table 1) In the human heart, five MLC isoforms exist that
are expressed in a tissue-specific manner: there are three
regulatory MLCs, namely two ventricular specific (VLC-2
and VLC-2*) and an atrial specific (ALC-2) (10). Two
essential light chains (MLC-1) have been described: ALC-
1 in the atrium and VLC-1 in the ventricle (Figure 1).
Human embryos express large amounts of ALC-1 in the
whole heart and in skeletal muscle. For this reason the
ALC-1 was designated as the embryonic MLC (MLC-
1emb) (10). A positive correlation between pressure over-
load in adult patients with valvular heart disease and left
ventricular ALC-1 expression exists. Normalization of the
hemodynamic state by valve replacement significantly
reduced hypertrophy and ALC-1 expression (11).
Phosphorylation of the MLC-2 has been shown to
increase tension development and Ca2+ sensitivity (12).
Recently, it has been demonstrated that there is a spatial
gradient across the heart in MLC phosphorylation altering
tension production in different wall sections (2).
The cardiac troponin complex comprises the inhibitory
(TnI), the Ca2+-binding (TnC) and the tropomyosin-
binding (TnT) subunits (13). Phosphorylation of TnI by
Protein Kinase A (PKA), which results from β-adrenergic
stimulation, leads to a decrease in the sensitivity of the
contractile proteins to Ca2+, which is accompanied by an
increased crossbridge cycling rate. These results indicate
that PKA-induced phosphorylation of TnI increases the
power output-generating capacity of cardiac myocytes
(14). In terminally failing hearts, TnI phosphorylation was
increased compared with normal heart (NH). This phos-
phorylation difference could underlie the reported
decrease of myofibrillar Ca2+ sensitivity of failing
myocardium (15). However, there are no data on TnI
phosphorylation in hypertrophied, non-failing human
myocardium. Therefore, in the present study TnI phos-
phorylation status of hypertrophied human myocardium
was investigated.
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Table 1
Nomenclature of myosin light chains and heavy chains
MHC Myosin heavy chain
MLC Myosin light chain
MLC-1 Essential myosin light chain
MLC-2 Phosphorylatable (regulatory) myosin light chain
ALC-1 Essential myosin light chain, atrial isoform
ALC-2 Phosphorylatable (regulatory) myosin light
chain, atrial isoform
VLC-1 Essential myosin light chain, ventricular isoform
VLC-2 Phosphorylatable (regulatory) myosin light
chain, ventricular isoform
VLC-2* Phosphorylatable (regulatory) myosin light
chain, additional ventricular isoform
Figure 1) Scheme of myosin heavy chain (MHC) and myosin light
chain (MLC) distribution in normal human heart. On the atrial level
there is α-MHC and the artrial MLC isoforms ALC-1 and ALC-2.
On the ventricular level only β-MHC and the ventricular MLC iso-
forms VLC-1 and VLC-2 can be detected. Each myosin molecule con-
sists of two MHCs, and on the head of each MHC there is one
molecule of MLC-1 and MLC-2
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MATERIAL AND METHODS
Patient population
Tissue from the left ventricular outflow tract was obtained
from 13 patients undergoing aortic valve replacement for
aortic stenosis (AS) and from 19 unrelated patients with
hypertropic obstructive cardiomyopathy (HOCM) under-
going transaortal subvalvular myotomy-myectomy (16) for
severe obstruction of the left ventricular outflow tract. The
clinical evaluation consisted of preoperative physical exam-
ination, electrocardiography (ECG), echocardiography and
cardiac catheterization. All the patients in this study  had a
normal ejection fractions (EF). Atrial tissue was taken from
the auricle of a patient undergoing mitral valve replace-
ment. Tissue from the interventricular septum was taken
from six healthy donor hearts that could not be transplant-
ed for technical reasons. Tissue samples were frozen in liquid
nitrogen immediately after resection. Informed consent was
obtained from all patients.
Tissue preparation
All tissue samples were immediately chemically skinned
or frozen in liquid nitrogen after resection. All biochem-
ical experiments were performed with demembranated
multicellular heart fibres (skinned fibres) prepared as
described previously (17) or with frozen tissue samples.
For the preparation of the skinned fibres, ventricular
fibre bundles (1 mm thick, between 2 and 5 mm long)
were incubated in a solution containing 20 mM imida-
zole, 10 mM NaN3, 5 mM ATP, 5 mM MgCl2, 4 mM
EGTA, 2 mM dithioerythritol, 50% glycerol and 1%
Triton X-100, pH 7, at 4°C for 20 h. Subsequently the
fibres were transferred into the same solution except
Triton X-100 and stored at –20°C. Tissue specimen for
analysis of phosphorylation levels were homogenized in
ice-cold trichloroacetate before further experimentation.
All tissue samples immediately frozen after resection
were stored at –80°C.
Biochemical analysis
Samples for high-resolution protein gel electrophoresis for
MHC analysis were prepared as follows. Briefly, samples
were homogenized in low-salt buffer (20 mmol/L KCl,
2 mmol/L KH2PO4, 1 mmol/L EGTA, pH 6.8, 1 mmol/L
phenylmethylsulphonylchloride and 100 µL N,N-
dimethyl formamide). The samples were then centrifuged
at 900 g for 10 min at 4°C. Laemmli’s buffer was added to
each sample. The preparation and composition of the gel
were  as described earlier (10). Gel samples (0.25 to 1 µg)
were loaded in a 3 µL volume onto 15-well gels. The stack-
ing and separating gels (0.75 mm thick) consisted of 4%
and 8% acrylamide, respectively; the stacking gels includ-
ed 5% glycerol. The gels were run at a constant voltage of
200 V for 30 h. The gels were fixed and silver-stained A
gel documentation system (Bio-Rad, Germany) was used
to scan the stained gels.
MLCs were analyzed by a high-resolution two-dimensional
gel electrophoresis two-dimensional polyacrylamide gel
electrophoresis [2D PAGE] technique. Isoelectric focusing
(first dimension) was performed in glass capillaries (12.5 cm
long, 1 mm inner diameter) using the pH gradient 4.5 to 5.5
(Pharmalytes, Parmacia, Sweden). The gels were run
overnight at 600 V constant load for the first dimensional
separation. The second dimension was a sodium dodecylsul-
phate electrophoresis, using slab gels 10.5×9.5 cm, 1 mm thick.
The gels were stained in Coomassie blue and the MLCs were
evaluated by computer-assisted scanner densitometry
(ScanPack, Biometra, Germany).
Human myocardial hypertrophy
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Table 2
Echocardiographic, hemodynamic and biochemical
data of patients with hypertropic obstructive
cardiomyopathy (HOCM) or aortic stenosis (AS)
Age IVS EF LVEDP
Diagnosis (years) Sex (mm) (%) (mmHg) ALC-1%
HOCM 56 f 17 62 12 1
HOCM 53 m 14 63 21 3
HOCM 38 m 28 66 16 4
HOCM 34 f 24 68 10 2
HOCM 56 f 17 69 6 8
HOCM 46 f 20 73 13 5
HOCM 60 f 24 72 17 14
HOCM 80 f 20 88 15 2
HOCM 63 f 20 76 15 10
HOCM 53 m 31 77 19 6
HOCM 48 m 24 76 1 11
HOCM 43 m 24 81 16 11
HOCM 64 f 22 81 20 13
HOCM 47 m 13 79 11 16
HOCM 46 m 15 72 1 20
HOCM 42 f 17 85 10 20
HOCM 62 f 16 82 20 22
HOCM 70 m 22 86 6 25
HOCM 56 f 17 80 17 32
AS 70 m 22 65 6 1
AS 56 f 17 64 9 2
AS 46 f 20 70 13 2
AS 60 f 24 74 17 2
AS 80 f 20 78 15 5
AS 43 m 15 74 24 6
AS 42 f 17 74 10 7
AS 68 f 16 78 20 9
AS 51 f 17 82 16 6
AS 72 m 22 80 6 16
AS 56 f 17 78 16 18
AS 46 f 20 76 13 24
AS 55 m 33 80 9 23
IVS Diameter of the interventricular septum in mm; LVEDP Left ventricular
end-diastolic pressure; EF Ejection fraction; ALC-1% Expression of the atrial
isofor m (ALC-1) of essential myosin light chain (MLC-1) as a percentage of
total MLC-1 (ie, ALC-1 + ventricular MLC isoform = 100%); f female; m male
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TnI phosphorylation status was analyzed by 2D PAGE
technique according to the above protocol. However, the
first dimension (isoelectric focusing) was a nonequilibrium
gel with inversed current. TnI phosphorylation level was
expressed as a percentage of total TnI, ie, TnI unphospho-
rylated + TnI phosphorylated = 100%.
Statistical analysis
All statistical analyses were performed using commercially
available statistic programs (Enzfitter, Epistat, Germany) on
Apple Macintosh or on IBM compatible PC. Values are
expressed as mean ± SEM. Significance analysis was per-
formed using the Student’s t test for unpaired values.
Regression analysis was performed by the least-squares
method.
RESULTS
Clinical data
In clinical terms there were homogeneous populations of
patients with HOCM and with AS. All patients had left
ventricular myocardial hypertrophy. The extent of hyper-
trophy of the interventricular septum was similar in both
patient groups. There were no significant differences in
hemodynamic data in the patient groups (Table 2).
MLC analysis
The MLC isoforms in frozen tissue and skinned fibres
were analyzed according to their isoelectric point and
molecular weight by 2D PAGE. The atrial isoform of the
essential light chain (ALC-1) had a higher molecular
weight and was more acidic than the ventricular isoform
(VLC-1). Figure 1 shows three original gels of tissue
preparations of the left ventricle from patients with
HOCM, AS and NH. All the fibres contained VLC-1 and
the two ventricular isoforms of the regulatory light
chains, VLC-2 and VLC-2*, but the preparat ion of
normal  myocardium showed no ALC-1 whereas
diseased myocardium had ALC-1 (11.4% of total essen-
tial light chains [MLC-1]). The mean ALC-1 expression
was 12.7±1%. Those patients who expressed ALC-1
had very different amounts ranging from 3.6% to 32.2%
ALC-1 (expressed as a percentage of total MLC-1, ie,
ALC-1 + VLC-1 = 100% MLC-1) (Table 2).
The ratio between essential light chains (MLC-1) and
regulatory light chains (MLC-2) showed no significant dif-
ference between patients with and without ALC-1. In the
NH, the MLC-1/MLC-2 ratio was 1.1±0.02%. In patients
with hypertrophied myocardium, an MLC-1/MLC-2 ratio of
1.26±0.78 and a ratio of 1.21±0.48 in patients without
ALC-1 (n=6), respectively was observed. The atrial isoform
of the regulatory light chain (ALC-2) was never observed in
our tissue. No tissue preparation-dependent differences in
results were found. In all individuals investigated here, the
content of ALC-1 in skinned fibres and in frozen tissue was
identical, indicating total incorporation of ALC-1 protein
into the sarcomere.
Phosphorylated MLC-2 promotes contractility and thus
counteracts the attenuating effects of phosphorylated
TnI. Therefore, MLC-2 phosphorylation in 2D PAGEs
was investigated Phosphorylated proteins are more
acidic, resulting in a shift of protein spots to the cathode.
However, virtually no MLC-2 phosphorylation in hypertro-
phied or normal human myocardium was found.
MHC analysis
The relative proportions of the two forms of the MHC
have been shown to be affected by a wide variety of patho-
logical and physiological stimuli. Hearts that express the
faster α-MHC produce more power than those expressing
the slower β-MHC, leading to the hypothesis that MHC
isoforms play a major role in the determination of cardiac
contractility. In the present study, therefore, the MHC
Ritter et al
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Figure 2) Original photographs of myosin light chains (MHC) in the myocardium of normal heart (NH) and in patients with aortic stenosis (AS) or
hypertropic obstructive cardiomyopathy (HOCM). All fibres contained VLC-1, VLC-2 and VLC-2*, but patients with hypertrophied myocardium con-
tained ALC-1 additionally. ALC-1 Atrial essential light chain; TM Tropomyosin; VLC-1 Ventricular essential light chain; VLC-2 and VLC-2* Isoforms
of the ventricular regulatory light chain. No phosphorylation of the regulatory light chains was detectable
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protein isoform content of our samples was determined.
No α-MHC was detectable in six NH and in 32 nonfailing
but hypertrophied human hearts (Figure 3).
TnI phosphorylation
TnI phosphorylation contributes to the impaired contractile
response of the myocardium to hemodynamic stress. Using
nonequilibrium 2D PAGE, TnI phosphorylation was
compared in patients with NH, HOCM and AS. However,
not significant change was found in the phosphorylation
level of TnI in the three patient groups. In NH, phosphory-
lated TnI was 12±3% (n=6), in AS it was 10±4%
(n=13; not significant) and in HOCM it was 13±4%
(n=19; not significant) (Figure 4).
Correlation between ALC-1 protein expression and EF
EF showed a mean value of 73±7%. Notably, there was a
statistically significant positive correlation between EF and
ALC-1 content of the myocardium. This is compatible with
a role of the ALC-1 in contractility in these disease states
(Figure 5). The high correlation coefficient of 0.76 (P<0.01,
F-test) further supports this hypothesis.
DISCUSSION
Gene expression in the overloaded rodent heart has been
studied extensively to highlight the molecular response of
the sarcomere. It is generally accepted that, in terms of con-
tractile proteins, a shift of MHC isoforms is part of the
response (18). Work from several groups has shown that in
the rodent heart, the MHC phenotype switches from the β-
MHC isoform to the α-MHC isoform during maturation and
vice versa under increased hemodynamic demands (19-24).
This conversion of the phenotype is associated with alter-
ations in the contractile and energetic behaviour of the con-
tractile apparatus. Expression of α-MHC leads to a higher
maximal shortening velocity, paralleled by a decreased econ-
omy in tension development (25). In turn, high amounts of
β-MHC decrease maximal shortening velocity and increase
economy of contraction (26), which is believed to improve
the function of the overloaded cardiomyocyte. These
findings raised the question of whether this mechanism
might also be operative in the human ventricle.
Immunohistochemical studies (27-29) and peptide maps
(28) revealed a tissue-specific expression of both MHC
isoforms, with a predominant expression of the α-MHC in
the atrium and the β-MHC in the ventricle. However,
quantification of the relative distribution of both isoforms in
the ventricle has proved difficult.
In two previous studies, α-MHC mRNA was detected in
the normal human heart. A downregulation of α-MHC
mRNA and an upregulation of β-MHC mRNA was report-
ed in the failing and hypertrophied human heart in analogy
to the rodent heart (29,30). However, these studies did not
address the problem of whether this switch at the RNA
level is reflected in MHC protein content.
Therefore, we here quantified the expression of α-MHC
protein in the normal and hypertrophied human ventricle
using high-resolution gel electrophoresis. We found no
traces of α-MHC protein expression in the normal or in the
hypertrophied ventricular human tissue. The MHC switch
for regulation of power output is not available in humans.
What might be the human correlate? We recently reported
that the human ventricular cardiomyocyte regulates its
Human myocardial hypertrophy
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Figure 3) Original photographs of myosin heavy chains (MHC) in the
myocardium of normal heart (NH) and in patients with aortic stenosis
(AS) or with hypertropic obstructive cardiomyopathy (HOCM). Ctr
Rabbit skeletal muscle myosin. Human atrial myocardium contained
α-MHC and β-MHC. Human ventricular myocardium from patients
with NH, AS or HOCM contained only β-MHC
Figure 4) Original photographs of troponin I (TnI) in the myocardium
of normal heart (NH) and in patients with aortic stenosis (AS) or
hypertropic obstructive cardiomyopathy (HOCM). TnI p indicates
phosphorylated TnI. There are no differences in the amount of
phosphorylated TnI in the three patient groups
Figure 5) Relation between the expression of atrial isoform of the essen-
tial myosin light chain (ALC-1) and ejection fraction (EF). Each circle
indicates one patient. The ALC-1 content is shown as a percentage of
total myosin light chain-1 (ALC-1 + VLC-1). AS Aortic stenosis;
HOCM Hypertrophic obstructive cardiomyopathy
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power output by changing essential MLC gene expression
rather than MHC gene expression (31,32). These observa-
tions imposed the question of whether an increase of
ALC-1 expression is also beneficial for the performance of
the human ventricle in vivo.
Here, we evaluated the effects of ALC-1 on cardiac
performance of the human heart in vivo in a clinical
homogeneous population of patients with HOCM and AS
without systolic dysfunction. We observed a close and
statistically significant correlation between essential MLCs
and contractility of the human ventricle in vivo. Increased
ALC-1 protein expression augmented cardiac contractility
in the human ventricle.
Myocardial performance could be influenced not only by
isoform shifting of MHCs and MLCs but also by phosphory-
lation of sarcomeric proteins. To determine the influence of
phosphorylation of sarcomeric proteins, we investigated the
phosphorylation levels of two key proteins of myocardial
contractility: VLC-2 and TnI in normal and hypertrophied
human heart. In our patients, we observed no phosphoryla-
tion of VLC-2 in the human ventricle and no significant
changes in TnI phosphorylation levels.
Expression of ALC-1 in diseased hearts raises the
question of whether there is a compensatory downregulation
of the ventricular isoform. According to the generally
accepted myosin model, the ratio between MLC-1 and
MLC-2 is 1 (ie, each MHC monomer is associated with one
essential and one regulatory light chain) (33). In our
patients we did not see a difference in the MLC-1/MLC-2
ratio in any of the groups, the ratio being about 1 in each
individual. Downregulation of the ventricular form of the
MLC-2 is to be expected in order to maintain the normal
MLC-1/MLC-2 ratio. This observation is in line with
previous studies on ALC-1 expression in the diseased human
myocardium. The hypertrophied right ventricle of children
with congenital heart diseases has been demonstrated to
express large amounts of ALC-1 up to adulthood (34).
Similarly, the dilated left ventricle of patients with ischemic
or dilative cardiomyopathy re-expressed ALC-1 (35). In
adult patients with valvular heart disease, a positive correla-
tion between systolic wall stress and left ventricular ALC-1
expression has been reported. Normalization of the hemo-
dynamic state by valve replacement significantly reduced
hypertrophy and ALC-1 expression (11). Recently, some
studies investigated the functional consequences of
re-expression of essential MLCs on the molecular level.
Myosin crossbridges with high amounts of ALC-1 had
a higher detachment rate and rate of force generation than
myosin with VLC-1 (31). These results showed that ALC-1
increased cycling kinetics of cardiac crossbridges in demem-
branated multicellular heart fibres, thus regulating the
contractile state of the heart. It was also shown that there is
a poitive correlation between the Ca2+ sensitivity of iso-
metric force development of skinned human heart fibres and
ALC-1 content (32). The inotropic effects of ALC-1 expres-
sion could be confirmed in vivo by a recent mouse model
overexpressing ALC-1 (36).
The molecular mechanism explaining the effects of
essential MLC on crossbridges in the heart may reside in the
mode of interaction of the essential MLC and actin. It
has been demonstrated that the amino terminal domain of
MLC-1 isoforms interacts with the carboxyl terminus of
actin. This interaction could be of functional importance
because the inhibition of this interaction increased force
production and shortening velocity of human heart
fibres (37). Interestingly, the primary structure of the most
amino terminal end of ALC-1 and VLC-1 is different:
ALC-1 contains two charges less compared with VLC-1,
suggesting a different binding affinity between ALC-1 or
VLC-1 and actin. In fact, binding of ALC-1 to actin was
found to be weaker than binding of VLC-1 to actin (38).
Weakening of the VLC-1-actin interaction by peptide
competition accelerated crossbridge cycling kinetics,
increased tension production and increased Ca2+ sensitivity
(39). These results are analogous to studies on muscle fibres
with an increased content of ALC-1 (31,32,39).
To our knowledge, this is the first study investigating
MHC and MLC composition in the following subsets of
patients with cardiac hypertrophy and normal systolic
function: HOCM and severe AS. In view of the relative
rarity of these patients (particularly HOCM with indica-
tion for operation) the numbers are large. It is noteworthy
that large pieces of tissue were used for measurements as
opposed to percutaneous biopsies with the inherent
problem of tissue heterogeneity (fibrosis). These two fac-
tors may also explain the relatively low variability of our
results compared with other studies in human tissue. We
demonstrate improved intrinsic contractile function in the
human ventricle in vivo, which significantly correlated
with enhanced ALC-1 protein expression, excluding an
MHC type of regulation. Expression of ALC-1 in the
hypertrophied human ventricle therefore may be an adap-
tational molecular mechanism to improve the inotropic
state of the human heart. ALC-1 expression turned out to
be a powerful compensatory mechanism to enhance power
output of the human heart.
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